Table 4.

Comparison of tumor-infiltrating lymphocyte density and programmed death ligand 1expression between newly diagnosed and matched recurrent glioblastoma specimens (Vienna retrospective cohort)

n = 18	Initial Tumor +,   ↓ Recurrence +	Initial Tumor −   ↓ Recurrence −	Initial Tumor +   ↓ Recurrence -	Initial Tumor −   ↓ Recurrence +
Diffuse/fibrillary tumoral PD-L1 expression	12/18 (66.7%)	1/18 (5.6%)	4/18 (22.2%)	1/18 (5.6%)
PD-L1+ epitheloid tumor cells	3/18 (16.7%)	15/18 (83.3%)	0/18 (0.0%)	0/18 (0.0%)
PD1+ TILs	0/18 (0.0%)	15/18 (83.3%)	3/18 (16.7%)	0/18 (0.0%)
CD3+ TILs	10/18 (55.6%)	3/18 (16.7%)	1/18 (5.6%)	4/18 (22.2%)
CD8+ TILs	10/18 (55.6%)	2/18 (11.1%)	4/18 (22.2%)	2/18 (11.1%)

Abbreviation: PD-L1, programmed death ligand 1.